Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of mocravimod as adjunctive and maintenance therapy around allogeneic hematopoietic cell transplantation for acute myeloid leukemia
MOH_2022-09-22_012069Phase 3Recruiting
- Sponsor
- Priothera
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mocravimod in acute myeloid leukemia (AML) (3 arms), sponsored by Priothera. Primary endpoint: Relapse-free survival. Started Jul 2022; status: recruiting.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-09-22_012069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-22_012069.